- Antisense Therapeutics (ANP) has raised $7.3 million for its Duchenne muscular dystrophy (DMD) treatment
- The company will issue 73 million shares at 10 cents each to new and existing shareholders
- Additionally, it aims to raise a further $1 million under a share purchase plan (SPP)
- The funds will be used to advance its applications of DMD treatment, known as ATL1102, in Europe and the U.S.
- Additionally, earlier this week, Antisense commenced its journey to dual list on the Frankfurt Stock Exchange
- On the market this afternoon, Antisense is down 8.70 percent and is trading for 10.5 cents per share
